High materiality7/10
Vertex Pharmaceuticals price target raised to $565 from $560 at Truist
Why it may matterVerify against the original reporting
modest upside implied by PT increase
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Truist Financial raises VRTX price target to $565 from $560.
- Target: $565 (from $560)
- Posted price: $488.56
- Analyst firm: Truist Financial
Key facts
- 01
Target: $565
- 02
Posted price: $488.56
- 03
Analyst firm: Truist Financial
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.